Sign inJoin waitlistJoin the waitlist

Jonathan Santoro

Psychiatry & Neurology / Neurology with Special Qualifications in Child Neurology · Childrens Hospital Los Angeles Medical Group Inc

Credentials: · · ·

History

Child Neurology
Children's Hospital Los Angeles
2013–2017
Keck School of Medicine of USC
2009–2013

Research

Racial Bias in the US Opioid Epidemic: A Review of the History of Systemic Bias and Implications for Care
Review · Cureus · 2018 · 116 citations
Genetic Acute Necrotizing Encephalopathy Associated with RANBP2: Clinical and Therapeutic Implications in Pediatrics
Review · Multiple Sclerosis and Related Disorders · 2020 · Last of 4 authors · Corresponding · 72 citations
Down Syndrome Disintegrative Disorder: A Clinical Regression Syndrome of Increasing Importance
Review · PEDIATRICS · 2020 · Last of 7 authors · Corresponding · 59 citations

SJ
Saba Jafarpour
29 papers · 4 as a resident
Mellad Khoshnood
26 papers · 20 as a resident
MR
Michael Rafii
22 papers
Nusrat Ahsan
13 papers
Eileen Quinn
12 papers
Lina Patel
12 papers
NS
Noemi Spinazzi
12 papers
Deepti Nagesh
10 papers
Ryan Kammeyer
10 papers · 2 as a fellow
Grace Gombolay
9 papers · 8 as a fellow
Melanie Manning
9 papers
Brian Skotko
8 papers

Grants

Neurodiagnostic, Proteomic, and Metabolomic Investigations into Down Syndrome Regression Disorder
National Institute of Child Health and Human Development · R01
Contact PI · $1.3M · Children's Hospital of Los Angeles
2025–2030
INCLUDE Clinical Researcher Training (ICRT)
National Institute on Aging · R25
PI · $866.5K · Magee-Women's Res Inst and Foundation
2025–2027
Non-Invasive Biometric Screening for Cerebrovascular Disorders in Persons with Down Syndrome.
National Heart, Lung, and Blood Institute · K23
Contact PI · $1.3M · Children's Hospital of Los Angeles
2021–2026
Mechanistic Investigation of Therapies for Down Syndrome Regression Disorder
National Institute of Child Health and Human Development · R61
PI · $1.5M · University of Colorado Denver
2022–2024

Clinical trials

An Open-Label Phase II Feasibility Study for the Use of Ublituximab in Adults With Down Syndrome Regression Disorder
Principal investigator · Not yet recruiting · Phase 2
Jonathan Santoro
2026–2030